Skip to main content
    S

    STRATA Skin Sciences Inc (SSKN)

    Official site

    MEDICAL DEVICES

    $0.00
    +0.00 (+0.00%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    STRATA Skin Sciences Inc (SSKN) Financials: Revenue, Profit and Cash Flow

    Updated Dec 31, 2025. Financial statements from company filings, amounts in US dollars.

    STRATA Skin Sciences reported revenue of $30.70M for the fiscal year ended Dec 31, 2025, down 8.5% from the year before. That year, net income was -$6.26M with a net margin of -20.4%, operating cash flow was -$2.79M and free cash flow was -$4.26M. The quarter ended Dec 31, 2025 had revenue of $9.29M and net income of $282.00K.

    Revenue and Margins

    The operating margin was -15.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue was little changed from $30.71M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$30.70M-8.5%58.3%-15.3%-20.4%
    Dec 2024$33.56M+0.6%57.3%-27.6%-30.1%
    Dec 2023$33.36M-7.8%55.3%-25.8%-32.5%
    Dec 2022$36.16M+20.6%60.2%-12.9%-15.3%
    Dec 2021$29.98M+29.8%66.2%-14.7%-9.0%
    Dec 2020$23.09M-26.9%61.2%-17.7%-19.1%
    Dec 2019$31.59M+5.8%64.2%-9.5%-12.0%
    Dec 2018$29.86M-6.0%57.3%-11.2%-13.5%
    Dec 2017$31.76M+3.4%59.1%-5.7%-67.7%
    Dec 2016$30.71MN/A58.8%-11.7%-10.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$30.70M$33.56M$33.36M$36.16M$29.98M$23.09M$31.59M$29.86M$31.76M$30.71M
    Cost of revenue$12.81M$14.34M$14.90M$14.39M$10.13M$8.96M$11.32M$12.73M$13.00M$12.64M
    Gross profit$17.88M$19.22M$18.46M$21.77M$19.85M$14.13M$20.27M$17.12M$18.77M$18.07M
    Research and development$421.00K$883.00K$1.32M$1.03M$1.43M$1.27M$1.00M$1.06M$1.71M$1.93M
    Operating income-$4.70M-$9.26M-$8.60M-$4.65M-$4.40M-$4.08M-$3.01M-$3.35M-$1.80M-$3.60M
    Net income-$6.26M-$10.09M-$10.83M-$5.55M-$2.71M-$4.41M-$3.79M-$4.03M-$21.51M-$3.33M
    EBITDA-$76.00K-$2.94M-$2.56M$1.20M$1.71M-$165.00K$1.99M$2.24M$9.44M$10.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue$9.29M$6.93M$7.66M$6.81M$9.58M$8.80M$8.44M$6.75M$8.69M$8.85M$8.25M$7.57M
    Gross profit$5.74M$4.18M$4.31M$3.65M$5.88M$5.29M$4.98M$3.08M$4.80M$4.95M$4.32M$4.39M
    Operating income$712.00K-$1.17M-$2.22M-$2.02M-$4.28M-$1.60M-$486.00K-$2.89M-$3.44M-$615.00K-$1.96M-$2.59M
    Net income$282.00K-$1.62M-$2.49M-$2.43M-$4.54M-$2.07M-$99.00K-$3.37M-$3.79M-$1.05M-$3.15M-$2.83M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $15.35M exceeded cash and equivalents by $7.44M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$30.52M$34.93M$42.02M$52.27M$46.59M$46.78M$47.34M$47.51M$39.13M$43.19M
    Current assets$15.60M$16.59M$15.54M$15.05M$19.97M$24.83M$23.55M$23.21M$10.75M$3.93M
    Cash and equivalents$7.91M$7.26M$6.78M$5.43M$12.59M$10.60M$8.13M$16.49M$4.07M$3.93M
    Total liabilities$27.61M$29.96M$29.33M$30.44M$21.18M$20.89M$18.69M$16.26M$19.25M$28.16M
    Short-term debt$15.35M$0$352.00K$355.00K$318.00K$8.75M$7.28M$252.00K$2.39M$2.05M
    Long-term debt$0$15.19M$15.04M$7.48M$7.32M$1.05M$0$7.14M$7.85M$21.78M
    Shareholder equity$2.91M$4.97M$12.69M$21.83M$25.41M$25.89M$28.65M$31.25M$19.88M$15.04M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets$30.52M$30.72M$30.72M$34.26M$36.16M$40.20M$39.58M$40.05M$42.02M$47.19M$55.20M$49.12M
    Total liabilities$27.61M$29.40M$30.41M$31.59M$31.18M$30.86M$30.09M$30.62M$29.33M$31.00M$38.30M$29.80M
    Cash and equivalents$7.91M$7.08M$5.97M$6.51M$7.26M$7.06M$5.48M$5.24M$6.78M$7.13M$9.03M$2.83M
    Shareholder equity$2.91M$1.31M$308.00K$2.67M$4.97M$9.34M$9.50M$9.43M$12.69M$16.19M$16.91M$19.32M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$2.79M$188.00K-$519.00K-$924.00K$1.51M$2.10M$2.23M$2.90M$4.14M$322.00K
    Capital expenditures$1.47M$1.64M$5.02M$3.74M$3.65M$2.16M$115.00K$13.00K$320.00K$0
    Free cash flow-$4.26M-$1.45M-$5.54M-$4.66M-$2.15M-$63.00K$2.11M$2.88M$3.82M$322.00K
    Share repurchasesN/AN/AN/AN/AN/AN/AN/A$2.34M$0N/A
    Investing cash flow-$1.47M-$1.64M-$5.02M-$4.37M-$7.13M-$2.16M-$2.79M-$1.78M-$2.19M-$868.00K
    Financing cash flow$3.58M$1.93M$6.86M-$500.00K$92.00K$2.55M-$296.00K$11.31M-$1.80M$1.17M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-$239.00K-$64.00K-$1.94M-$550.00K$703.00K-$302.00K$591.00K-$804.00K$1.37M-$2.02M$947.00K-$817.00K
    Capital expenditures$312.00K$1.02M$61.00K$199.00K$504.00K$62.00K$345.00K$725.00K$1.72M$194.00K$1.70M$1.79M
    Free cash flow-$551.00K-$1.08M-$2.00M-$749.00K$199.00K-$364.00K$246.00K-$1.53M-$347.00K-$2.21M-$756.00K-$2.61M
    Last 12 quarters

    Frequently Asked Questions About SSKN

    What is STRATA Skin Sciences' annual revenue?

    STRATA Skin Sciences reported revenue of $30.70M for the fiscal year ended Dec 31, 2025.

    How fast is STRATA Skin Sciences' revenue growing?

    Revenue was down 8.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.3%.

    Is STRATA Skin Sciences profitable?

    No. STRATA Skin Sciences reported net income of -$6.26M for the fiscal year ended Dec 31, 2025, with a net margin of -20.4%.

    How much free cash flow does SSKN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$2.79M minus capital expenditures of $1.47M produced free cash flow of -$4.26M.

    How much debt does STRATA Skin Sciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $15.35M and cash and equivalents of $7.91M.